TO THE EDITOR
In Leukemia (January 2005), 1 Dr Piazza reported a BCR-ABL mutation D276G by sequencing the BCR-ABL tyrosine kinase (TK) domain of Ph þ leukemic cells from 14 imatinib-resistant patients. The mutation was associated with aggressive chronic myeloid leukemia (CML), while in vitro functional analysis using mutants demonstrated moderated resistance.
We report two others cases of D276G mutation and draw attention to the peculiar clinical and cytogenetic aspects of these patients. Mutations in the TK domain of BCR-ABL were investigated for resistant or refractory CML patients after 1 year of imatinib treatment. 2, 3 Briefly, after extraction of total RNA from peripheral blood samples, a seminested reverse transcriptasepolymerase chain reaction (RT-PCR) was performed to amplify a 1298-bp fragment including the entire kinase domain was followed by direct sequencing as previously described. 4 When mutation was detected in a patient for the first time, the procedure was repeated using a second RNA sample. Detection was confirmed if the same mutation was detected in repeat analysis.
Between November 2001 and November 2003, eight different mutations (three T315I, G250A, E255K, M244V, two D276G) in the TK domain were detected in our patients. Mutation D276G was identified in two CML patients at the time of acute transformation occuring 'on therapy' (patients A and B). Both were in the late chronic phase (CP)-CML previously resistant to interferon a (IFNa) therapy.
Patient A was diagnosed as having CP CML in May 1994 (Sokal and Hasford score were low risk) and started imatinib therapy (400 mg/day) in July 2000 (Novartis protocol 113). A complete hematological response (CHR) was achieved 1 month later followed by a major cytogenetic response (MCR) 2 months later. In Patient B was diagnosed with CP CML in December 1996 (Sokal and Hasford scores were low risk). Imatinib therapy was initiated in January 2000 (400 mg/day) (Novartis protocol 110), and CHR was obtained 1 month later followed by a CCR in October 2000. In June 2003, CCR failed and the D276G mutation was detected for the first time. Transformation into myeloid blast crisis with detection of trisomy 8 and deletion of chromosome 17 occurred 1 month later and the patient died 3 months later despite administration of increasing doses of imatinib (800 mg/day).
In this study, D276G mutation was detected in two CML patients just before acute transformation. This mutation concerned two of eight mutations observed in this small cohort of patients (imatinib resistant or refractory CP, resistant or refractory accelerated phase and acute phase), a proportion similar to that in the Piazza's study (2/8). Our both patients lost cytogenetic response and exhibited a D276G mutation and cytogenetic abnormalities. Then, a swift acute transformation of CML was observed.
D276G mutation, located on the b3-aC-loop, induced destabilisation of the inactive conformation of the enzyme responsible for resistance. 1, 6 In vitro functional analysis demonstrated that a strong resistance was shown with a double mutant D276S/D279S exhibiting an increased kinase activity.
6 By contrast, a single D276 mutation induced a moderated resistance in spite of increased kinase activity.
1,5 So, we suggested that several mechanisms are necessary to induce a strong resistance and an aggressive clinical evolution.
Although D276G mutation is not frequently detected in imatinib resistant patients, 7,8 we conclude that mutation at position 276 is not so rare in our cohort of CP-CML mutated resistant patients (2/8 mutations). This rate may be due to a number of patients lower than those reported in the literature. 7, 8 Moreover, this mutation could be associated with rapid transformation after a period of cytogenetic response and development of clonal cytogenetic abnormalities in acute phase. D276G is detected in both Ph þ ALL and CML resistant patients, 1 two diseases with different clinical course. But the clinical evolution and the cytogenetic abnormalities have not been described by the authors specifically for the CML patients. So, in the light of this peculiar evolution, we would like to know if the clinical and molecular and cytogenetic characteristics of Piazza's cases were similar in order to show whether D276G mutation contributes alone or in association with clonal evolution or with second mutation to induce clinical resistance to imatinib and acute transformation. These informations would probably permit us to clarify mechanism of resistance due to D276G mutation. In their letter to the editor, Leguay et al 1 present the clinical and molecular characteristics of two patients affected by chronic myeloid leukemia (CML) and treated with imatinib. These two patients showed an aggressive clinical course: they developed resistance to the drug and died soon after the evolution to blast crisis (BC: one lymphoid, one myeloid). Sequencing analysis of the Abl catalytic domain of samples taken during relapse showed the presence of mutation D276G in both cases. Thus, the authors conclude that mutation D276G could be linked to an aggressive disease course and a rapid transformation to acute phase, associated with a particularly poor prognosis.
We recently published 2 a case report on a patient affected by Bcr/Abl p190 acute lymphoblastic leukemia (ALL) treated with imatinib who developed resistance to the drug and in whom mutation analysis revealed mutation D276G. This patient was diagnosed with ALL on April 2001, started standard chemotherapy regimen and obtained a complete cytogenetic remission (CCR), remaining positive for p190 at the molecular level. On August 2001, he started on imatinib 800 mg daily and remained in cytogenetic remission until January 2002 when bone marrow aspirate showed 70% blasts. He died on November 2002, despite receiving chemotherapy followed by autografting.
A second case of D276G mutation identified in our laboratory is a chronic phase (CP) CML patient who was diagnosed on March 1995. The patient started on imatinib, 400 mg daily, in January 2000. After 12 months of treatment, he showed only a minor cytogenetic response; thus, his dose was increased to 800 mg. He obtained a CCR after 6 months, but remained positive on PCR. Clonal mutational screening on a bone marrow sample, taken 3 months after the achievement of CCR (October 2001), revealed the presence of mutation F359V on 6/10 clones analyzed. In a successive analysis (May 2003), mutation F359V was found to be present in 10/10 clones and mutation D276G in 2/10 clones. The patient subsequently lost the CCR but has not progressed to the accelerated phase (AP)/BC, although he developed additional cytological abnormalities.
Also, in the original description of D276G mutation, 3 the patient first developed a F359V mutation while in remission from a Ph þ ALL, and showed the D276G at the time of clinical relapse.
A further review of the literature available also identified a fifth case of Ph þ leukemia resistant to imatinib carrying mutation D276G 4 ; in this case also, the clinical course of the disease was aggressive, with D276G observed at the time of BC development.
Clinical data from these patients carrying mutation D276G show, in general, an aggressive course, according to what is suggested by Leguay and co-workers, with the D276G mutation detected at the time of disease progression in four out of five cases. However, in the analysis of these data, prudence is required. Two patients were affected by ALL; thus, their clinical course is not easily comparable with the CML patients; our second patient carried mutation D276G only in a fraction (20%) of the resistant clones; thus, the clinical characteristics of this patient could be linked to the most represented mutation (F359V). Moreover, mutation D276G was present as a double mutant with F359V, and it is known that these two mutations act via different molecular mechanisms; 5 thus, an additive effect cannot be ruled out. Finally, it is important to underline that at the moment, to our knowledge, there is no convincing molecular mechanism supporting the aggressive course of mutation D276G other than its increased kinetic activity. 
